194 related articles for article (PubMed ID: 24023668)
1. Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells.
Liu L; Yang Z; Xu Y; Li J; Xu D; Zhang L; Sun J; Xia S; Zou F; Liu Y
PLoS One; 2013; 8(8):e73038. PubMed ID: 24023668
[TBL] [Abstract][Full Text] [Related]
2. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
[TBL] [Abstract][Full Text] [Related]
3. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice.
Shen B; Chu ES; Zhao G; Man K; Wu CW; Cheng JT; Li G; Nie Y; Lo CM; Teoh N; Farrell GC; Sung JJ; Yu J
Br J Cancer; 2012 Apr; 106(9):1486-94. PubMed ID: 22472882
[TBL] [Abstract][Full Text] [Related]
4. PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells.
Chearwae W; Bright JJ
Br J Cancer; 2008 Dec; 99(12):2044-53. PubMed ID: 19018263
[TBL] [Abstract][Full Text] [Related]
5. Combined effect of honokiol and rosiglitazone on cell growth inhibition through enhanced G0/G1 phase arrest in hepatoma cells.
Chen HC; Hsu HT; Weng JW; Chang YF; Hsia CY; Lee HC; Chi CW
J Chin Med Assoc; 2016 Aug; 79(8):415-21. PubMed ID: 27094504
[TBL] [Abstract][Full Text] [Related]
6. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.
Yuan Y; Zhang A; Huang S; Ding G; Chen R
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F393-402. PubMed ID: 21123490
[TBL] [Abstract][Full Text] [Related]
7. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
8. 15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis.
Nakata S; Yoshida T; Shiraishi T; Horinaka M; Kouhara J; Wakada M; Sakai T
Mol Cancer Ther; 2006 Jul; 5(7):1827-35. PubMed ID: 16891469
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
[TBL] [Abstract][Full Text] [Related]
10. The combinatory effects of PPAR-γ agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells.
Wang Y; Tan H; Xu D; Ma A; Zhang L; Sun J; Yang Z; Liu Y; Shi G
Int J Mol Med; 2014 Jul; 34(1):262-8. PubMed ID: 24820432
[TBL] [Abstract][Full Text] [Related]
11. 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity.
Shin SW; Seo CY; Han H; Han JY; Jeong JS; Kwak JY; Park JI
Clin Cancer Res; 2009 Sep; 15(17):5414-25. PubMed ID: 19690198
[TBL] [Abstract][Full Text] [Related]
12. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
[TBL] [Abstract][Full Text] [Related]
13. Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners.
Chiba T; Suzuki E; Yuki K; Zen Y; Oshima M; Miyagi S; Saraya A; Koide S; Motoyama T; Ogasawara S; Ooka Y; Tawada A; Nakatsura T; Hayashi T; Yamashita T; Kaneko S; Miyazaki M; Iwama A; Yokosuka O
PLoS One; 2014; 9(1):e84807. PubMed ID: 24454751
[TBL] [Abstract][Full Text] [Related]
14. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
[TBL] [Abstract][Full Text] [Related]
15. PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404.
Zhang W; Wu N; Li Z; Wang L; Jin J; Zha XL
Cancer Biol Ther; 2006 Aug; 5(8):1008-14. PubMed ID: 16775433
[TBL] [Abstract][Full Text] [Related]
16. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
Shim J; Kim BH; Kim YI; Kim KY; Hwangbo Y; Jang JY; Dong SH; Kim HJ; Chang YW; Chang R
Int J Oncol; 2010 Jan; 36(1):223-31. PubMed ID: 19956851
[TBL] [Abstract][Full Text] [Related]
17. Nox2-derived ROS in PPARγ signaling and cell-cycle progression of lung alveolar epithelial cells.
Tickner J; Fan LM; Du J; Meijles D; Li JM
Free Radic Biol Med; 2011 Aug; 51(3):763-72. PubMed ID: 21664456
[TBL] [Abstract][Full Text] [Related]
18. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression.
Cao LQ; Shao ZL; Liang HH; Zhang DW; Yang XW; Jiang XF; Xue P
Cancer Lett; 2015 Apr; 359(1):127-35. PubMed ID: 25592041
[TBL] [Abstract][Full Text] [Related]
19. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
